84 related articles for article (PubMed ID: 18710181)
1. Review: erythropoiesis-stimulating agents increase mortality and venous thromboembolism in cancer-associated anemia.
Thomé S
ACP J Club; 2008 Aug; 149(2):8. PubMed ID: 18710181
[No Abstract] [Full Text] [Related]
2. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.
Dronca RS; Steensma DP
Nat Clin Pract Oncol; 2008 Sep; 5(9):504-5. PubMed ID: 18648351
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
4. Review: erythropoiesis-stimulating agents increase mortality and venous thromboembolism in cancer-associated anaemia.
Thomé S
Evid Based Med; 2008 Oct; 13(5):149. PubMed ID: 18836117
[No Abstract] [Full Text] [Related]
5. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
Pirker R
Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
[TBL] [Abstract][Full Text] [Related]
6. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
Schiavetto I; Pedrazzoli P; Basilico V; Siena S
Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
[TBL] [Abstract][Full Text] [Related]
7. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
8. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
9. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
10. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
11. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars".
Locatelli F; Becker H
Oncologist; 2009; 14 Suppl 1():16-21. PubMed ID: 19762513
[TBL] [Abstract][Full Text] [Related]
12. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
13. Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia.
Samaras AT; Bennett CL
Am J Hematol Oncol; 2008 Aug; 7(8):327-332. PubMed ID: 21850277
[No Abstract] [Full Text] [Related]
14. Review: erythropoiesis-stimulating agents increase mortality in patients with cancer.
Matulonis U
Evid Based Med; 2009 Dec; 14(6):182. PubMed ID: 19949184
[No Abstract] [Full Text] [Related]
15. Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?
Bohlius J
Nat Clin Pract Oncol; 2008 Dec; 5(12):688-9. PubMed ID: 18936789
[TBL] [Abstract][Full Text] [Related]
16. The link between cancer and venous thromboembolism: a review.
Kessler CM
Am J Clin Oncol; 2009 Aug; 32(4 Suppl):S3-7. PubMed ID: 19654481
[TBL] [Abstract][Full Text] [Related]
17. Role of anticoagulation in the management of pancreatic cancer.
Sohail MA; Saif MW
JOP; 2009 Mar; 10(2):82-7. PubMed ID: 19287098
[TBL] [Abstract][Full Text] [Related]
18. [Venous thromboembolism and cancer].
Descourt R; Jezequel P; Couturaud F; Leroyer C; Girard P
Rev Pneumol Clin; 2008 Dec; 64(6):282-9. PubMed ID: 19084207
[TBL] [Abstract][Full Text] [Related]
19. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological prophylaxis of venous thromboembolism in contemporary radical retropubic prostatectomy: does concomitant pelvic lymphadenectomy matter?
Jessie BC; Marshall FF
Int J Urol; 2008 Oct; 15(11):951-6. PubMed ID: 18775031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
